1.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2.https://www./web-exclusives/fda-approves-nivolumabipilimumab-for-advanced-hcc
3.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label,parallel-group, randomised, phase 2 trial
4.2020 ASCO
5.2020 CSCO原发性肝癌诊疗指南
6.https://www./Guidelines/Gastrointestinal-Cancers/Hepatocellular-Carcinoma/eUpdate-Treatment-Recommendations2
7.https://www./news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer
8.Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study [published online ahead of print, 2020 May 13]. Lancet Oncol. 2020;S1470-2045(20)30110-8. doi:10.1016/S1470-2045(20)30110-8
9.Nong Xu, et.al. Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC). ASCO 2019.Abstract 4042.
10.Lin Shen, et.al. Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multi- center, open label phase II trial. ASCO 2019.Abstract 4031